IPCA Laboratories Limited — Updates, 24-09-2025: Press Release
24-09-2025 | 05:07 pm
24-09-2025 | 05:07 pm
Ipca Labs announced a tech transfer and joint development deal with BioSimilar Sciences PR LLC for an anti-cancer/anti-inflammatory biosimilar. This shifts development to Puerto Rico, bolstering U.S. supply chains and jobs. Ipca gains milestone fees and royalties from future sales.
No comments yet. Be the first to comment!
